Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Olaparib and Durvalumab in Patients With Germline BRCA-Mutated Metastatic Breast Cancer (MEDIOLA): An Open-Label, Multicentre, Phase 1/2, Basket StudyLancet Oncol 2020 Aug 06;[EPub Ahead of Print], SM Domchek, S Postel-Vinay, SA Im, YH Park, JP Delord, A Italiano, J Alexandre, B You, S Bastian, MG Krebs, D Wang, SN Waqar, M Lanasa, J Rhee, H Gao, V Rocher-Ros, EV Jones, S Gulati, A Coenen-Stass, I Kozarewa, Z Lai, HK Angell, L Opincar, P Herbolsheimer, B Kaufman
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.